Inactive Instrument

FUREN Group Pharmaceutical Co.,Ltd.

600781

CNE000000NM4

FUREN Group Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter 2019

April 28, 2019

FUREN Group Pharmaceutical Co., Ltd. reported earnings results for the first quarter 2019. For the period, the company reported basic earnings per share of CNY 0.34.

Latest news about FUREN Group Pharmaceutical Co.,Ltd.

FUREN Group Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	28/04/23	CI
FUREN Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	30/10/22	CI
FUREN Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	30/08/22	CI
FUREN Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	29/04/22	CI
FUREN Group Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	28/04/22	CI
FUREN Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	29/10/21	CI
Furen Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	30/08/21	CI
Furen Group Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	29/04/21	CI
Furen Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	29/04/21	CI
Furen Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	30/10/20	CI
Furen Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020	28/08/20	CI
Furen Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2019	19/06/20	CI
FUREN Group Pharmaceutical Co., Ltd. Appoints Zhu Wenliang as General Manager	11/06/20	CI
Furen Group Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2020	29/04/20	CI
FUREN Group Pharmaceutical Co., Ltd. Elects Huang Dianying as Independent Director	07/01/20	CI
FUREN Group Pharmaceutical Co., Ltd.(SHSE:600781) dropped from Shanghai Stock Exchange Health Care Sector Index	13/12/19	CI
Furen Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2019	30/10/19	CI
Furen Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2019	31/08/19	CI
Shanghai Furen Industrial Co., Ltd Announces Cash Dividend for the Year 2018, Payable on July 22, 2019	14/07/19	CI
FUREN Group Pharmaceutical Co., Ltd.(SHSE:600781) added to Shanghai Stock Exchange Health Care Sector Index	25/06/19	CI
FUREN Group Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter 2019	28/04/19	CI
FUREN Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Year 2018	18/04/19	CI
Furen Pharmaceutical Group Industry Co., Ltd. Provides Earnings Guidance for the Year 2018	27/01/19	CI
FUREN Group Pharmaceutical Co., Ltd. cancelled the transaction announced on December 20, 2015	20/12/18	CI
Furen Pharmaceutical Group Industry Co. Ltd. Announces Earnings Results for the Nine Months of 2018	24/10/18	CI

Chart FUREN Group Pharmaceutical Co.,Ltd.

Duration

Period

Chart FUREN Group Pharmaceutical Co.,Ltd.

More charts

FUREN Group Pharmaceutical Co., Ltd., formerly Furen Pharmaceutical Group Industry Co., Ltd., is a China-based company principally engaged in the manufacturing, wholesale and retail of pharmaceuticals. The Company's principal business is the manufacture of proprietary Chinese medicines, including capsules, tablets, granules, gels, injections, suspensions, drops, syrups and others. The Company mainly distributes its products in the domestic market.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVO NORDISK A/S	+31.37%	595B
JOHNSON & JOHNSON	-2.60%	367B
MERCK & CO., INC.	+20.83%	334B
ABBVIE INC.	+5.69%	289B
ASTRAZENECA PLC	+14.83%	239B
NOVARTIS AG	+9.93%	211B
ROCHE HOLDING AG	-6.95%	203B
AMGEN INC.	+10.77%	171B
PFIZER, INC.	+0.10%	163B

Other Pharmaceuticals